⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 24, 2018Expert Opinion on Drug DiscoveryOpen Access

Challenges with biomarkers in cancer drug discovery and development

Ecaterina Ileana Dumbrava Funda Meric‐Bernstam Timothy A. Yap

View Full Paper

Ask AI

Bookmark

Share

Abstract

Precision medicine or personalized cancer therapy involves the tailoring of antitumor treatments to the individual clinical features, tumor molecular profiles, and associated microenvironment of pa...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dumbrava et al. (2018) studied this question.

synapsesocial.com/papers/6a6f20ed31a3df824327911b https://doi.org/10.1080/17460441.2018.1479740

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Targeting fibroimmune remodeling in androgenetic alopecia: emerging opportunities for RNA-based drug discoveryExpert Opinion on Drug Discovery · Thu,
2Current applications of isothermal titration calorimetry for lead optimizationExpert Opinion on Drug Discovery · Wed,
3From stochastic systems to governed intelligence: a neurosymbolic path for pharmaExpert Opinion on Drug Discovery · Mon,
4Rethinking zebrafish anxiety models in drug discovery and precision psychiatryExpert Opinion on Drug Discovery · Thu,
5Organoids in drug discovery and development: emerging technologies to transition beyond animal modelsExpert Opinion on Drug Discovery · Mon,

More from Expert Opinion on Drug Discovery

Using molecular modeling and QSAR-based design strategies for advancing the development of therapeutic solute carrier 6 (SLC6) transporter ligandsSun,
Lymph node models of chronic lymphocytic leukemia for translational evaluation of new drug candidatesMon,
Strategy-based design for the identification of next generation β-lactam antibiotics that evade resistance from Gram-negative pathogensSun,
The rapid emergence of small molecule RNA modulator hit discovery: unlocking the potentialTue,
Design considerations for in silico drug discovery platform that can accelerate targeted drug repurposing: a focus on rare, neglected, and emerging diseasesFri,